



### "Update on developments for pre-clinical diagnosis of vCJD..doc"

Document Type:	Formal
File Title:	CMO ALB BSU - NIBSC - 2006-2007
File Reference:	ZDA/023/004
	No Marking
Filed by:	Ann Selman/POLICY/DOH/GB on 02/10/2009 at 15:42
Created by:	Kazimierz K Tomaszczyk on 24/07/2006 at 11:18

#### Named Security Prior To Moving To Archive:

Nobody
Ann Selman/POLICY/DOH/GB
All readers of the document database

Kazimierz K  
Tomaszczyk/ISD8/DOH/GB  
24/07/2006 11:18

To Ann Selman/POLICY/DOH/GB **GRO-C**  
cc Mark Thomas/NUR-PS/DOH/GB **GRO-C**  
bcc  
Subject Update on developments for pre-clinical diagnosis of  
vCJD..doc

Ann, FYI.

Kaz

#### Kaz Tomaszczyk

Finance Manager - Administration  
Standards & Quality Group Business Team  
Department of Health  
Wellington House, Room 310  
133-155 Waterloo Road  
London  
SE1 8UG  
Direct line: **GRO-C**  
Direct fax: **GRO-C**  
GTN: **GRO-C**  
Ext: **GRO-C**  
email: [k.tomaszczyk@doh.gov.uk](mailto:k.tomaszczyk@doh.gov.uk) **GRO-C**

For finance guidance and forms please visit the [Standards & Quality GBT Finance Website](#)

----- Forwarded by Kazimierz K Tomaszczyk/ISD8/DOH/GB on 24/07/2006 11:17 -----

Ailsa Wight  
21/07/2006 16:54

To: Mark Thomas/NUR-  
PS/DOH/GB **GRO-C** Kazimierz K Tomaszczyk/ISD8/DOH/GB

cc: Rowena  
Jecock/PH6/DOH/GB [GRO-C] John  
Stephenson/RD2/DOH/GB [GRO-C]  
Subject: Update on  
developments for pre-clinical diagnosis of vCJD..doc



RESTRICTED - Policy

Mark

Spoke to Kaz in your absence just now.

I explained the background to the attached draft submission. CMO has always taken a close interest in CJD matters, and the aim is really to give him, and MS(PH), a heads up that diagnostic/screening tests for CJD could become available in the not too distant future (perhaps a year or so).

Obviously there would be significant public health benefits of a test. Although it is not possible to give any meaningful indication of likely costs at this stage, we think the submission would be remiss if it did not mention that there could be potential financial pressures as a result of any test coming on stream. These pressures are likely to be on the NBS, as well as on the NHS. There are also ongoing RDD pressures, which we are addressing with RD colleagues.

We would like to acknowledge that we have flagged with you in principle, as per para 15 of the draft, simply on a 'no surprises' basis in the absence of being able to provide anything more concrete.

Rowena or I would be very happy to discuss.

Many thanks

Ailsa

Dr Ailsa Wight

Head of Programme

General Health Protection

524 Wellington House

133/155 Waterloo Road

London

SE1 8UG

[GRO-C]

----- Forwarded by Ailsa Wight/PH6/DOH/GB on 21/07/2006 16:15 -----

Ailsa Wight

21/07/2006 16:13

To: Rowena  
Jecock/PH6/DOH/GB, Neil Ebenezer/PH5/DOH/GB, john  
stephenson  
cc: Stephen  
Dobra/SAT/DOH/GB [GRO-C] Gerard  
Hetherington/HPIHSD/DOH/GB [GRO-C] Darren  
Hughes/PH5/DOH/GB [GRO-C] Janet Gibson/PH6/DOH/GB [GRO-C]  
bcc:  
Subject: Update on  
developments for pre-clinical diagnosis of vCJD..doc

Please see attached.

Following discussion with Gerard and Rowena I have revamped, so that the emphasis and focus is on the diagnostics update as originally intended. I'd be particularly grateful if you could address the relevant DNs there.

In line with this change of emphasis, and also given recent developments, explicit reference to prion filters has been removed.

Rowena has tried to contact Geoff Rees re Finance implications but I will send separately to Mark Thomas so he is sighted (see para 15) and can offer comments.

We agreed we'd ideally like to get this to David H next week, so grateful for comments by return if possible.

Thanks

Dr Ailsa Wight  
Head of Programme  
General Health Protection  
524 Wellington House  
133/155 Waterloo Road  
London  
SE1 8UG  

GRO-C



- Update on developments for pre-clinical diagnosis of vCJD..doc